首页> 外文期刊>Heart >A systematic review on the safety and efficacy of percutaneous edge-to-edge mitral valve repair with the MitraClip system for high surgical risk candidates
【24h】

A systematic review on the safety and efficacy of percutaneous edge-to-edge mitral valve repair with the MitraClip system for high surgical risk candidates

机译:使用MitraClip系统对高手术风险候选者进行经皮边缘到边缘二尖瓣修复的安全性和有效性的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background MitraClip implantation has emerged as a viable option in high surgical risk patients with severe mitral regurgitation (MR). We performed the present systematic review to assess the safety and efficacy of the MitraClip system for high surgical risk candidates with severe organic and/or functional MR. Methods Six electronic databases were searched for original published studies from January 2000 to March 2013. Two reviewers independently appraised studies, using a standard form, and extracted data on methodology, quality criteria, and outcome measures. All data were extracted and tabulated from the relevant articles' texts, tables, and figures and checked by another reviewer. Results Overall 111 publications were identified. After applying selection criteria and removing serial publications with accumulating number of patients or increased length of follow-up, 12 publications with the most complete dataset were included for quality appraisal and data extraction. All 12 studies were prospective observational studies. Immediate procedural success ranged from 72-100%; 30 day mortality ranged from 0-7.8%. There was a significant improvement in haemodynamic profile and functional status after implantation. One year survival ranged from 75-90%. No long term outcomes have been reported for high surgical risk patients. Conclusions MitraClip implantation is an option in managing selected high surgical risk patients with severe MR. The current evidence suggests that MitraClip can be implanted with reproducible safety and feasibility profile in this subgroup of patients. Further prospective trials with mid- to long-term follow-up are required.
机译:背景技术MitraClip植入已成为具有严重二尖瓣反流(MR)的高手术风险患者的可行选择。我们进行了目前的系统评价,以评估MitraClip系统对患有严重器质性和/或功能性MR的高手术风险候选人的安全性和有效性。方法从2000年1月至2013年3月的六个电子数据库中检索原始发表的研究。两名评价者使用标准表格独立评估研究,并提取方法,质量标准和结果指标方面的数据。所有数据均从相关文章的文本,表格和图形中提取并制成表格,并由另一位审阅者进行检查。结果共鉴定111篇出版物。在应用选择标准并删除患者人数不断增加或随访时间增加的系列出版物后,纳入了具有最完整数据集的12种出版物进行质量评估和数据提取。所有12项研究均为前瞻性观察研究。即时程序成功率为72-100%; 30天死亡率为0-7.8%。植入后血流动力学特征和功能状态有了显着改善。一年生存率在75-90%之间。没有关于高手术风险患者的长期预后的报道。结论MitraClip植入是选择治疗具有严重MR的高手术风险患者的一种选择。目前的证据表明,MitraClip可以在该亚组患者中植入,并且具有可重复的安全性和可行性。需要对中长期随访的进一步前瞻性试验。

著录项

  • 来源
    《Heart》 |2014年第6期|473-478|共6页
  • 作者单位

    The Systematic Review Unit, The Collaborative Research (CORE) Group, Sydney, Australia,Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark;

    The Systematic Review Unit, The Collaborative Research (CORE) Group, Sydney, Australia;

    The Systematic Review Unit, The Collaborative Research (CORE) Group, Sydney, Australia;

    The Systematic Review Unit, The Collaborative Research (CORE) Group, Sydney, Australia;

    The Systematic Review Unit, The Collaborative Research (CORE) Group, Sydney, Australia;

    Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark;

    Department of Cardiology, Rigshospitalet, Copenhagen, Denmark;

    Division of Cardiac Surgery, Ospedale San Raffaele, Milan, Italy;

    The Systematic Review Unit, The Collaborative Research Group (CORE), Sydney, Australia Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, the University of Sydney, Sydney, NSW 2050, Australia;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号